☰

Carrie M. Mosher, Ph.D. - Publications

Affiliations: 
2008 University of Washington, Seattle, Seattle, WA 
Area:
Pharmacology, Biochemistry
Tree Info Similar researchers PubMed Report error

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH, Radominska-Pandya A. Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. The Journal of Pharmacology and Experimental Therapeutics. 340: 46-55. PMID 21972237 DOI: 10.1124/Jpet.111.184721  0.358
2010 Mosher CM, Court MH. Comparative and veterinary pharmacogenomics. Handbook of Experimental Pharmacology. 49-77. PMID 20204583 DOI: 10.1007/978-3-642-10324-7_3  0.325
2009 Mosher CM, Tai G, Rettie AE. CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. The Journal of Pharmacology and Experimental Therapeutics. 329: 938-44. PMID 19258521 DOI: 10.1124/Jpet.109.150706  0.469
2008 Mosher CM, Hummel MA, Tracy TS, Rettie AE. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. Biochemistry. 47: 11725-34. PMID 18922023 DOI: 10.1021/Bi801231M  0.559
2005 Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, Rettie AE, Tracy TS. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Molecular Pharmacology. 68: 644-51. PMID 15955872 DOI: 10.1124/Mol.105.013763  0.553
Show low-probability matches.